Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The Neurochemical Niche of Glioblastoma Stem Cells

EF 2018-19

Résumé
Brain cancer is a nasty disease, and virtually all patients die within two years of developing its most aggressive tumour called glioblastoma. Though decades of research have helped us better understand the biology of these tumours, we have surprisingly overlooked their home. Here, I propose to investigate what makes the brain the only home in which glioblastoma can grow. I suspect it has to do with one of the brain's unique chemicals: dopamine. We know that new treatments will only work if they target the cells in the tumour that act like stem cells. Early evidence suggests that these cells may exploit dopamine to grow the tumour in the brain. I intend to figure out if this is the case. I will first add dopamine to these cells (isolated from human glioblastoma tumours) and study if/how it makes them change. Then, adhering to Canada's animal care guidelines, I will work with genetically-altered mice that accept human cells and enable controlled release of dopamine from neurons. Following injection of human glioblastoma stem cells into the brains of these mice, I will either shine light to stimulate the release of dopamine or add a drug to inhibit dopamine release into the human cells' surrounding environment. Then, I will see if/how altered dopamine levels affected tumour growth. Dopamine helps us think, feel pleasure, and move our limbs. So it makes sense that unusual levels of dopamine in the brain is linked to disorders like schizophrenia, drug addiction, and Parkinson's. Today, many dopamine-modifying drugs are approved to treat those disorders. If my theory is supported by my findings, drugs that decrease the brain's dopamine levels may weaken the growth of glioblastoma, thus enabling us to provide patients with new treatments to tackle this deadly brain cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406548
Name
Ware Matthaeus A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Neurochemical Niche of Glioblastoma Stem Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Cancer; Cancer; Cancer Stem Cells; Chemogenetics; Drug Therapy; Glioblastoma; Neuro-Oncology; Neurochemical Signalling; Neuroscience; Optogenetics
Abstract
Brain cancer is a nasty disease, and virtually all patients die within two years of developing its most aggressive tumour called glioblastoma. Though decades of research have helped us better understand the biology of these tumours, we have surprisingly overlooked their home. Here, I propose to investigate what makes the brain the only home in which glioblastoma can grow. I suspect it has to do with one of the brain's unique chemicals: dopamine. We know that new treatments will only work if they target the cells in the tumour that act like stem cells. Early evidence suggests that these cells may exploit dopamine to grow the tumour in the brain. I intend to figure out if this is the case. I will first add dopamine to these cells (isolated from human glioblastoma tumours) and study if/how it makes them change. Then, adhering to Canada's animal care guidelines, I will work with genetically-altered mice that accept human cells and enable controlled release of dopamine from neurons. Following injection of human glioblastoma stem cells into the brains of these mice, I will either shine light to stimulate the release of dopamine or add a drug to inhibit dopamine release into the human cells' surrounding environment. Then, I will see if/how altered dopamine levels affected tumour growth. Dopamine helps us think, feel pleasure, and move our limbs. So it makes sense that unusual levels of dopamine in the brain is linked to disorders like schizophrenia, drug addiction, and Parkinson's. Today, many dopamine-modifying drugs are approved to treat those disorders. If my theory is supported by my findings, drugs that decrease the brain's dopamine levels may weaken the growth of glioblastoma, thus enabling us to provide patients with new treatments to tackle this deadly brain cancer.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ware, Matthaeus A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~